PDCD1 and glioblastoma: Although CTLA-4 and PD-1 blockade are the focus of the basic research and clinical attention, continued exploration of additional checkpoints may lead to development of combination treatment strategies that can improve responses and expand immune checkpoint blockade to a greater number of GBM patients [58, 77].